Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, FDC has informed that U.S. Food and Drug Administration (FDA) had conducted an inspection at Company’s manufacturing facility located at Baddi, Himachal Pradesh which is dedicated for manufacturing Cephalosporin Oral dosage forms. The said audit has been successfully completed by the US FDA with ‘No observations’ (Zero 483’s).
The above information is a part of company’s filings submitted to BSE.
